Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

NCT00663260 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

631

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Dapagliflozin
DRUG: Dapagliflozin
DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]